Sydney, Australia 29 November 2023 Highlights Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with 67Cu-SAR-bisPSMA at the highest dose level of 12GBq. No dose limiting toxicities (DLTs) have been reported to date. Only one participant had one adverse…
Sydney, Australia 7 November 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE (NCT05407311)1, for participants…
Sydney, Australia 26 October 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG (“PSI”), a global contract research organisation committed to on-time enrollment in radiopharmaceutical clinical trials, have entered into…
Sydney, Australia 3 October 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first patient in its theranostic 64Cu/67Cu SAR-Bombesin Phase I/II trial in metastatic castrate resistant prostate…
Sydney, Australia 13 September 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce favourable imaging data from the Phase II diagnostic investigator-initiated trial (IIT) of 64Cu SAR-Bombesin in prostate cancer,…
Sydney, Australia 25 August 2023 Highlights First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight. Cohort 3 was successfully completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE at a dose of 275MBq/kg body…
Sydney, Australia 25 August 2023 First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. Cohort 2 was recently completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq. Data…
Sydney, Australia 10 August 2023 Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq. No dose limiting toxicities (DLTs) have been reported in cohort 2. The Safety Review Committee…
Sydney, Australia 7 August 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an exclusive license from Memorial Sloan Kettering Cancer Center (MSK). The license is to intellectual property that…
Sydney, Australia 26 July 2023 Highlights Cohort 3 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE at a dose of 275MBq/kg body weight. Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned. Recruitment of cohort 4 is open at clinical sites in the US at…